Unicycive Therapeutics, Inc. (UNCY) is a clinical-stage biotechnology company developing therapies for kidney disease. Its lead candidate, oxylanthanum carbonate (OLC), is an oral phosphate binder for hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis, and its second asset, UNI-494, targets acute kidney injury. With the stock trading near $3.60 and a sharp range of analyst views, investors are asking whether the share price can climb toward $25.
For this analysis, seven individual, attributable analyst price targets were reviewed, from H.C. Wainwright ($13), Benchmark ($13), StoneX ($15), B. Riley Securities ($20), Maxim Group ($30), Guggenheim ($37), and Noble Financial ($50). The arithmetic mean of these targets is about $25.4, which rounds to a central target of $25. The low-to-high range is exceptionally wide, from $13 to $50.
All seven carry Buy or Speculative Buy ratings, which is why aggregators describe the stock as a "Strong Buy." Yet the spread between the lowest and highest target — a nearly four-fold difference — is a reminder that this is a binary, pre-commercial biotechnology situation rather than a stable earnings story. Notably, a couple of older, pre-2026 targets as high as $72 (Westpark Capital) and $90 (Piper Sandler) were excluded as clearly stale because they predate the company's second Complete Response Letter (CRL), a major value-changing event.
Analysts generally agree on the scientific profile of OLC — robust phosphate control with a materially lower pill burden — but they differ sharply on how much probability to assign to approval, reimbursement uptake, and the financing needed to reach commercialization.
The stock recently traded near $3.60, with a market capitalization around $99 million and a 52-week range of roughly $3.35 to $8.74. A move to $25 would require an upside of about 590%, which is a very large move even by speculative biotech standards.
The path is not a gradual earnings climb but an event-driven repricing. In June 2026, the FDA issued a second CRL tied to the same third-party manufacturing deficiencies cited in 2025, sending shares down about 39% in a single session. On October 21, 2026, the FDA accepted a resubmitted New Drug Application (NDA) that includes Chemistry, Manufacturing, and Controls (CMC) data from a new vendor whose facility previously received a "No Action Indicated" inspection status, setting a Prescription Drug User Fee Act (PDUFA) target action date of March 25, 2027. Approval — or a clear signal of approval — would be the primary catalyst for any move toward higher targets.
The stock remains in a broad downtrend from its May 2026 high near $8.56. The 52-week low near $3.35 is the key support level to watch, while the $4.69 level — where shares settled after the June 2026 CRL — and the $7-to-$8 zone above it represent meaningful resistance. A durable recovery toward any of the higher analyst targets would likely require sustained buying through these levels, not just a single headline-driven spike.
Analyst price targets on this stock generally reflect a roughly 12-month research horizon, though the practical timeline is dominated by the March 25, 2027 PDUFA date. Investors should watch for FDA inspection updates on both manufacturing vendors, the next earnings release and cash-burn commentary, any financing or partnership announcements, and revisions to analyst targets as the PDUFA date approaches. Developments in the securities litigation also warrant attention. No timing for reaching the target is implied here.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, event-driven name like Unicycive, these signals can help traders discover opportunities, monitor positions, and spot shifting trends more efficiently than manual screening. Exploring these AI-generated signals alongside fundamental research can provide a more complete view of evolving momentum.
The question of whether Unicycive can reach $25 is ultimately a question about FDA approval. The $25 figure is not a guarantee but the arithmetic mean of seven current analyst targets spanning $13 to $50, all of which sit far above the recent price near $3.60 and imply a very large move of roughly 590%. The bull case rests on a clean approval and strong launch economics for OLC; the bear case rests on a third manufacturing setback, dilution, and litigation. With the resubmission accepted and a March 2027 PDUFA date set, the next several months of regulatory and financing updates will determine whether that gap narrows or widens.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, UNCY has been loosely correlated with NVCT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if UNCY jumps, then NVCT could also see price increases.
| Ticker / NAME | Correlation To UNCY | 1D Price Change % | ||
|---|---|---|---|---|
| UNCY | 100% | -1.84% | ||
| NVCT - UNCY | 52% Loosely correlated | -0.48% | ||
| ICU - UNCY | 46% Loosely correlated | -3.03% | ||
| VTGN - UNCY | 42% Loosely correlated | -1.41% | ||
| LQDA - UNCY | 34% Loosely correlated | +0.16% | ||
| OGEN - UNCY | 34% Loosely correlated | -0.05% | ||
More | ||||